Member Info for stocksaint

"I think David Nugent will support the company until EBITDA positive so no more requirement for a fund raise. A further 1m in March should see us through."

You really believe that when cash burn is at least £350k per month. Each new hospital that takes up the baby product only adds about £50k to GDR's revenue annually!? They need many more hospitals to take this up before they can break even - would say they need about 200 for that.

"Then the company has no excuse for not delivering finally."

You're joking. They'll need a lot more than this extra 1 million to get anywhere near break-even point.

Actual payment for this case is just too far out in the future/uncertain

I think it's a lot more than 1 billon anyway.

Roger, So you now think DN would support a placing at 0.2p, when he rejected it a couple of weeks ago? (Or why would the likes of PH suddenly now offer much more favorable terms than before??

Milei's success makes it more likely that Argentina can right itself and Burford will eventually be paid. But to my mind actually getting the money is some way off (probably minimum 3 years).

Hamilton is right. There's sitll no clear way that GDR will raise money seeing as last proposal was so overwhelmingly rejected. (DN has only raised his stake by a tiny margin since the last TR1, so it's not clear what his intentions/plan is at all. And the board have not indicated that anything has changed on the funding score either and dialogue with DN).

In 2 months...

This is a day traders share for sure. Absolutely crazy it went up that much on a MOU for a pilot! There wasn't even any details about the pilot like the number of hospitals involved.

I find it quite amusing. GDR haven't even said how many hospitals are involved in this pilot. (They probably don't even know).

Incredible rise given such a weak RNS.

Nissan, you probably put too much weight on a comment that wasn't repeated in their RNSs, actual written updates.

It was definitely Riverfort. The RNS is still there: March 2023.

Can only assume they're worried GDR could go bust.

Afraid the next RNS may well be about administration. 2 months of money left. They did try but the shareholders voted no.

I thought the RNS said they'd tried to reach out to him and not had a response??

I'd be surprised if Allenby and Peel Hunt would bother offering the same deal to the same bunch of shareholders, just weeks after they rejected it.

Busicat, All what you say is possible. But there isn't any hard evidence to suggest NHS England were even planning to bypass the longer NICE process and adopt the product. I have read previously that NHS England had a formal process where they would need to launch a public consultation to take such action on a treatment. And there would have been an announcement of a public consultation (which in fact there never has been for this).

The ongoing NICE process still stands (which means the product could be adopted across England and Wales in 2027).

Excellent post from Franky. Agree with it all except for last sentence. I personally don't think "PE" will be interested. They tend to be only after businesses with big established revenue/profit streams in this kind of sector.

GDR are listing a third shareholder on the register:

Nortrust Nominees Limited 37,676,600 3.68%

RNS from 6 August 2024:

genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, announces that its Chief Executive Officer ("CEO"), James Cheek, has left the Company with immediate effect by mutual agreement.

James has been succeeded as CEO by Dr. Gino Miele PhD, currently Chief Scientific Officer ("CSO") who has been with the Company since 2011, serving as R&D Director and since September 2023 as CSO and an Executive Board Director. Prior to joining the Company Gino served as an Associate Director for clinical translational genomics at Wyeth and Pfizer.

I see what you mean though Nissan, his linkedin profile actually claims he was CEO until February 2025. Interesting as Gino became CEO in August 2024!!!! seems odd.